Esophageal squamous cell carcinoma

Researchers are testing an experimental injectable drug called ALK-N001 in adults with advanced gastrointestinal tumors, including esophageal and colorectal cancers that have worsened after standard treatment. The phase II trial gives the drug intravenously every two weeks at one…

Researchers are testing whether giving sacituzumab tirumotecan plus toripalimab before surgery helps people with locally advanced esophageal squamous cell carcinoma. Participants receive three cycles of the combination, then undergo standard surgery to remove the tumor. The main …

This trial tests whether giving a combination of immunotherapy (sintilimab) and two chemotherapy drugs (paclitaxel polymeric micelles and cisplatin) before surgery can help people with a certain type of esophageal cancer. The treatment aims to shrink tumors and improve the chance…

This phase III trial compares an experimental drug called FH-006 with standard chemotherapy in people with advanced esophageal squamous cell carcinoma that has progressed after initial treatment. The study aims to see if FH-006 can help patients live longer. Participants will be …

This early-stage trial is testing an investigational drug called BL-ARC002 in people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to find a safe dose and to see if the drug shows any signs of shrinking tumors. Participants receive the …

This trial tests whether using a dye to identify and remove only the sentinel lymph nodes (the first nodes cancer might spread to) during esophageal cancer surgery is as effective as removing all nearby lymph nodes. The study includes 200 adults with early-stage esophageal squamo…

This phase 2 trial is testing whether giving a combination of adebrelimab (an immunotherapy), thymalfasin (an immune booster), and chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. The study will enroll about 31 adults…

This trial is investigating whether adding an experimental immunotherapy drug, retlirafusp alfa, to standard chemotherapy and radiation can help people with locally advanced esophageal squamous cell cancer that cannot be surgically removed. Participants will receive two cycles of…

This trial is testing whether artificial intelligence can create 'digital twin' models of esophageal cancer patients to predict how they will respond to a combination of immunotherapy and chemotherapy. The study will compare the AI's predictions against real outcomes in patients …

This phase II trial tests a personalized approach for people with locally advanced esophageal cancer. After initial chemoimmunotherapy, patients whose tumors shrink well go straight to surgery, while those with less response receive additional radiotherapy before surgery. The goa…

This early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…

This phase II trial tests a combination of three drugs—Becotatug Vedotin, Tislelizumab, and low-dose Lenvatinib—in people with advanced esophageal squamous cell carcinoma whose cancer has progressed after first-line therapy. The study aims to see if this triple therapy can shrink…

This trial investigates whether tailoring treatment based on specific biomarkers can improve outcomes for people with advanced esophageal squamous cell carcinoma that has spread. Participants are randomly assigned to receive either standard chemotherapy plus a PD-1 inhibitor or t…

This phase II trial tests a combination of two drugs—sacituzumab tirumotecan (a targeted chemotherapy) and tagitanlimab (an immunotherapy)—as a second-line treatment for people with advanced esophageal squamous cell carcinoma or gastric/gastroesophageal junction adenocarcinoma. T…

This trial tests a new drug called becotatug vedotin, given together with standard chemotherapy (cisplatin) and radiation, for people with a type of advanced esophageal cancer. The main goals are to find the safest dose and see how well the combination works. About 12 participant…

This phase 2 trial tests a single drug called PD-1/IL-2α-bias bispecific antibody fusion protein in people with advanced or metastatic esophageal squamous cell carcinoma whose cancer worsened after prior immunotherapy and chemotherapy. The drug is designed to boost the immune sys…

This study tests whether a short course of radiation followed by the immunotherapy drug tislelizumab plus chemotherapy can improve outcomes for people with a type of esophageal cancer that can be surgically removed. About 50 participants will receive either a low or high dose of …

This study tests whether matching drug combinations to a patient's tumor genetics can help when standard immunotherapy stops working. About 90 people with advanced esophageal cancer will get one of three treatment pairs based on their cancer's molecular profile. The goal is to se…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This Phase 3 trial tests a new drug called HS-20093 against standard chemotherapy in 494 people with advanced esophageal cancer that has worsened after initial treatment. The goal is to see if HS-20093 helps people live longer and controls the tumor better. Participants will rece…

This study tests whether adding a new drug called retlirafusp alfa to standard chemotherapy before surgery can help shrink tumors in people with a type of esophageal cancer. About 33 adults with locally advanced esophageal squamous cell carcinoma will receive the combination trea…

This Phase 3 trial tests whether using a blood test that detects tumor DNA can guide who needs extra therapy after esophageal cancer surgery. Participants will either receive a combination of immunotherapy (tislelizumab), chemotherapy, and radiation, or be monitored without addit…

This early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …

This study tests a drug called adebrelimab combined with chemotherapy before deciding on surgery for people with a certain type of esophageal cancer. About 200 participants will receive the treatment first. If the cancer disappears completely on scans, they will be randomly assig…

This phase 2 trial will test whether adding the experimental drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 49 participants will receive three cycles of the combination, then under…

This phase 2 trial tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemoradiotherapy can help people with locally advanced esophageal cancer whose initial chemo-immunotherapy did not work. About 40 participants will receive the treatment…

This study tests a new combination of three drugs—becotatug vedotin, tislelizumab, and chemotherapy—for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The goal is to see if adding the targeted drug becotatug vedotin to standard im…

This study tests a new combination of drugs (QL1706 plus chemotherapy) as the first treatment for people with advanced or spreading esophageal cancer. About 50 adults who have not had prior treatment will receive the combo to see if it shrinks tumors and how long it keeps the can…

This study tests a combination of two drugs, SHR-1701 and liposomal irinotecan, in 33 adults with esophageal squamous cell carcinoma who have already received immunotherapy. The goal is to see if the combo can shrink tumors or stop them from growing. Participants will receive the…

This study tests whether a combination of three drugs (camrelizumab, chemotherapy, and ivarmacitinib) given before surgery can help people with a type of esophageal cancer. The goal is to see if the treatment can eliminate or shrink the tumor enough to improve surgical outcomes. …

This phase 2 trial tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery in 26 patients with locally advanced esophageal cancer. The goal is to see if this approach can completely eliminate cancer cells in the removed tis…

This phase II trial is testing whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) and a targeted therapy (lenvatinib) to standard chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. The main goal is to…

This study tests a personalized approach for people with advanced esophageal cancer that cannot be removed by surgery. Doctors will use MRI scans to guide a custom combination of chemotherapy, radiation, and immunotherapy. The goal is to see if this tailored treatment can help ke…

This study tests whether a new combination of drugs (anlotinib hydrochloride plus benmelstobart) works better than the current standard treatment (toripalimab plus chemotherapy) for people with advanced esophageal cancer that has certain gene mutations. The trial will include 578…

This phase 3 study tests a new drug called SYS6010 against standard chemotherapy in people with advanced esophageal cancer that has worsened after at least one prior treatment. About 436 participants will be randomly assigned to receive either SYS6010 or a standard chemo drug. Th…

This phase 3 trial will compare two surgical techniques for esophageal cancer: totally minimally invasive esophagectomy (TMIE) using only keyhole incisions, versus a hybrid approach that combines keyhole and open chest surgery. The study aims to see if TMIE reduces severe complic…

This study tests whether a short course of radiation followed by three cycles of the immunotherapy drug serplulimab plus chemotherapy can help shrink esophageal tumors before surgery. It includes 22 adults with resectable esophageal squamous cell carcinoma. The goal is to see if …

This phase II trial tests whether a special PET scan (FAPI-PET/CT) can help doctors choose the best treatment for people with resectable esophageal cancer. After two cycles of chemoimmunotherapy, the scan results will guide whether patients continue with more chemoimmunotherapy o…

This phase II trial tests a combination of three drugs (adebrelimab, nimotuzumab, and chemotherapy) given before surgery to 22 patients with resectable esophageal squamous cell carcinoma. The main goal is to see if the cancer disappears completely after treatment. If it works, th…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with resectable locally advanced esophageal squamous cell carcinoma. About 390 participants will be randomly assigned to receive either torip…

This study tests a new surgical technique for people with esophageal cancer. The method uses a special dye to check blood flow and wraps the surgical connection with a piece of belly tissue to prevent leaks. About 73 adults will receive this procedure to see if it lowers the risk…

This study tests a standardized care plan for esophageal fistula, a severe complication of advanced esophageal cancer where a hole forms between the esophagus and windpipe or chest. The plan includes sealing the hole with stents, antibiotics, nutrition support, and further cancer…

This study tests whether the drug toripalimab, given after surgery, can help prevent esophageal cancer from returning in patients at high risk of recurrence. About 435 adults who have already had chemotherapy and immunotherapy before surgery will either receive toripalimab or be …

This study tests a new drug called QL1706 combined with chemotherapy for people with a type of esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough so that surgery can be done successfully. 24 adults with this cancer will receive the drug …

This study is for people with esophageal cancer that did not shrink after initial treatment. It tests whether adding low-dose radiation to a combination of immunotherapy (toripalimab) and chemotherapy can improve outcomes. Participants will receive the treatment before surgery, a…

This study tests a new combination of drugs for people with advanced or metastatic esophageal squamous cell carcinoma who have not had prior treatment. The experimental therapy includes SYS6010 (a targeted antibody-drug conjugate) plus SG001 (an immunotherapy), with or without st…

This Phase 3 trial tests whether the immunotherapy drug toripalimab can help prevent cancer from growing in people with advanced esophageal cancer who have already received chemotherapy and radiation. About 340 participants will be randomly assigned to receive toripalimab or just…

This early-stage study tests a new drug called IPM514 in 36 people with advanced esophageal cancer that cannot be removed by surgery or has spread. The drug is given as a shot, and the main goals are to check safety and find the best dose. Researchers will also look for early sig…

This study tests a chemotherapy drug (TAS-102) combined with radiation in people aged 65-85 with advanced esophageal cancer. The goal is to find the safest dose and see if the combination helps control the cancer and improves survival. About 45 participants will take part across …

This study tests whether giving two drugs—camrelizumab (an immunotherapy) and palbociclib (a targeted therapy)—before surgery can safely shrink tumors in people with esophageal cancer that can be removed. About 41 adults with resectable esophageal squamous cell carcinoma will rec…

This phase II trial tests whether a single low dose of radiation to all visible tumors can help immunotherapy work again in people with advanced esophageal cancer that has stopped responding to standard treatment. Thirty-two adults will receive the radiation and continue their or…

This early-phase trial is testing a new approach for people with recurrent or metastatic head/neck cancer or esophageal cancer. The treatment combines a virus that delivers endostatin directly into tumors with an immunotherapy drug (PD-1 inhibitor). The goal is to see if the comb…

This study asks whether two PET/CT scans taken before treatment can predict how well patients with esophageal cancer respond to immunotherapy plus chemotherapy given before surgery. Adults with stage II to IVA esophageal squamous cell carcinoma will receive both scans, and those …

This trial aims to develop and validate a standardized MRI protocol for staging esophageal squamous cell carcinoma and assessing how well tumors respond to neoadjuvant therapy. About 500 adults scheduled for surgery will be enrolled, with some undergoing MRI before surgery and ot…

This study tests whether a special dye, called indocyanine green, can help surgeons find cancer that has spread to nearby lymph nodes during esophageal cancer surgery. About 144 adults with esophageal cancer will take part. If the dye works well, it may allow doctors to remove fe…

Researchers are testing whether giving an anti-PD-1 immunotherapy drug together with anlotinib after surgery can prevent or delay the return of esophageal squamous cell carcinoma. The trial enrolls adults aged 18 to 75 who had chemotherapy plus immunotherapy before surgery, then …

This study tests whether a personalized, supervised exercise program done at home can improve physical function in people who have finished treatment for gastroesophageal cancer. About 20 survivors will receive tailored aerobic and resistance exercises via video calls. The goal i…

This study tests whether using a laryngeal mask instead of a breathing tube during esophageal cancer surgery can reduce complications and speed up recovery. About 500 adults with resectable esophageal cancer will be randomly assigned to one of two anesthesia methods. The goal is …

Researchers are reviewing medical records of 100 people with esophageal squamous cell carcinoma who received immunotherapy plus chemotherapy before surgery to remove the cancer. The study examines when and where cancer returns and which patient traits, treatment details, scan res…

This study compares two standard pre-surgery treatments for a common type of esophageal cancer: chemoradiotherapy (radiation plus chemo) versus immunochemotherapy (immunotherapy plus chemo). Using data from 400 patients' medical records, researchers will analyze which approach is…

This study follows 400 people with esophageal squamous cell carcinoma who have received chemo-immunotherapy before surgery. During standard tumor removal, surgeons will carefully label and analyze each lymph node station to see which ones still contain cancer. The goal is to map …

This study will follow 72 adults with early-stage gastroesophageal cancer to see how their physical function changes during chemotherapy. Participants will have their physical abilities measured at several points over six months. The goal is to understand which patients are at ri…

This study will check if certain immune cells, called precursor exhausted T cells, found in cancer-free lymph nodes can predict whether esophageal cancer completely disappears after immunotherapy. Researchers will study 88 patients before surgery to see if these cells are better …

This observational study will enroll 158 adults with advanced or recurrent esophageal cancer who plan to receive PD-1 inhibitor immunotherapy. Researchers want to see if a high level of a specific immune cell type (precursor exhausted T cells, or Tpex) in cancer-free lymph nodes …

This study will look at tumor samples from 12 people with esophageal cancer before and after they receive standard chemotherapy plus immunotherapy followed by surgery. Using advanced techniques like single-cell analysis, researchers aim to understand how the tumor environment cha…

This study will follow 750 adults in France who undergo endoscopic submucosal dissection (ESD) for early esophageal cancer or precancerous Barrett's esophagus. Researchers will track how well the procedure removes the cancer, how often it comes back, and whether additional treatm…

This study aims to develop an AI system that helps doctors choose the best treatment for esophageal cancer. Researchers will collect data from 7,000 patients, including medical images and tissue samples, to train a computer model that predicts how well a patient will respond to t…

This study will follow 255 people with esophageal cancer to understand how the disease changes over time. Researchers will use advanced tests like genetic analysis, imaging, and immune profiling. The goal is to improve how doctors predict cancer progression and response to treatm…